The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Doublets vs triplets in elderly/frail patients with myeloma: the importance of dose modification
In this video, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, discusses factors to consider when selecting between doublets and triplets for elderly/frail patients with multiple myeloma. Dr Pawlyn highlights the tolerability of daratumumab in combination with lenalidomide and dexamethasone (DRd) in this patient population, and further comments on the importance of dose modification in this setting. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
